Humacyte
Our vision is to be the global leader in engineering regenerative medicine products to save and improve patient lives.
165 employees · est. 2004 · Durham, United States
Vascular Therapies
Reducing Surgical Stenosis for Patients with Kidney Disease
7 employees · est. 2001 · United States
Vascular Therapies is the older company (2004 vs 2001); Humacyte is the larger of the two.
Side-by-Side Comparison
| Metric | Humacyte | Vascular Therapies |
|---|---|---|
| Founded | ||
| Founded | 2004 | 2001 older |
| Headquarters | ||
| Headquarters | Durham, United States | United States |
| Employees | ||
| Employees | 165 larger | 7 |
| Industry | ||
| Industry | Biotechnology, Medical Devices | Biotechnology, Health Care, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | IPO | Series Unknown |
| Total Funding | ||
| Total Funding | $833.10M | $89.96M |
| Funding Rounds | ||
| Funding Rounds | 16 | 9 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Regenerative Medicine, Medical Technology, Tissue Engineering, Organ Regeneration, Vascular Surgery, Bioengineered Tissues, Clinical Trials, Acellular Tissues, FDA Expedited Review, RMAT Designation, Vascular Trauma, Hemodialysis, Peripheral Arterial Disease, Cell And Tissue Applications | Vascular Therapy, Kidney Disease, Surgical Stenosis, Clinical Trials, Sirolimus Formulation, Vascular Access, Arteriovenous Fistula, Hemodialysis, Patient Outcomes |
| Website | ||
| Website | humacyte.com | vasculartx.com |
About Humacyte
Humacyte is a biotechnology startup based in the United States with a vision to be the global leader in engineering regenerative medicine products to save and improve patient lives. The company is on a mission to deliver universally implantable bioengineered human tissues and organs designed to impr...
About Vascular Therapies
Vascular Therapies is a biotechnology company founded in 2001, headquartered in the United States, and focused on enhancing patient outcomes by addressing surgical stenosis in patients with kidney and vascular disease. The company's flagship product is Sirogen™, an investigational sirolimus formulat...
We will tell you when either one moves
BounceWatch watches Humacyte and Vascular Therapies for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Humacyte and Vascular Therapies — by email.
Frequently Asked Questions
Compare Humacyte with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Humacyte on 9 Jun 2026, and Vascular Therapies on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
